People with mental health and addictive (MHA) disorders smoke at high rates and require tobacco treatment as a part of their comprehensive psychiatric care. Psychiatric care providers often do not address tobacco use among people with mental illness, possibly owing to the belief that their patients will not be able to quit successfully or that even short-term abstinence will adversely influence psychiatric status. Progress in the development of treatments has been slow in part because smokers with current MHA disorders have been excluded from most smoking cessation trials. There are several smoking cessation treatment options, including psychological and pharmacological interventions, that should be offered to people with an MHA disorder who smoke. Building motivation and readiness to quit smoking is a major challenge, and therefore motivational interventions are essential. We review the treatment options for people with tobacco dependence and MHA disorders, offer recommendations on tobacco assessment and tailored treatment strategies, and provide suggestions for future research. Treatment efficacy could be enhanced through promoting smoking reduction as an initial treatment goal, extending duration of treatment, and delivering it within an integrated care model that also aims to reduce the availability of tobacco in MHA treatment settings and in the community.
ZiedonisDHitsmanBBeckhamJC, Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008;10(12):1691–1715.
2.
HitsmanBBorrelliBMcChargueDE, History of depression and smoking cessation outcome: A meta-analysis. J Consult Clin Psychol. 2003;71(4):657–663.
3.
HitsmanB.Smoking cessation treatment in patients with depression: Outcomes, relapse vulnerability factors, and targeted interventions. Eur Neuropsychopharmacol. 2006;16(Suppl 4):S200.
4.
AddingtonJel-GuebalyNCampbellW, Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry. 1998;155(7):974–976.
5.
ChengappaKNKambhampatiRKPerkinsK, Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. J Clin Psychiatry. 2001;62(7):503–508.
6.
GeorgeTPZiedonisDMFeingoldA, Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157(11):1835–1842.
7.
HertzbergMAMooreSDFeldmanME, A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol. 2001;21(1):94–98.
8.
HallSM. Nicotine interventions with comorbid populations. Am J Prev Med. 2007;33(6 Suppl):S406–S413.
9.
KalmanDMorissetteSBGeorgeTP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106–123.
10.
McChargueDEGulliverSBHitsmanB.Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment?Addiction. 2002;97(7):785–793; discussion 795–800.
11.
OlivierDLubmanDIFraserR.Tobacco smoking within psychiatric inpatient settings: Biopsychosocial perspective. Aust N Z J Psychiatry. 2007;41(7):572–580.
12.
WilhelmKWedgwoodLNivenH, Smoking cessation and depression: Current knowledge and future directions. Drug Alcohol Rev. 2006;25(1):97–107.
13.
PetersonALHryshko-MullenASCortezY.Assessment and diagnosis of nicotine dependence in mental health settings. Am J Addict. 2003;12(3):192–197.
14.
MontoyaIDHerbeckDMSvikisDS, Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice. Am J Addict. 2005;14(5):441–454.
15.
BerkMNgFWangWV, Going up in smoke: Tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord. 2008;110(1–2):126–134.
16.
FioreMCJaenCRBakerTB, Treating tobacco use and dependence: 2008 update. Rockville (MD): US Department of Health and Human Services, Public Health Service; 2008.
17.
NiauraRShadelWG. Assessment to inform smoking cessation treatment. In: AbramsDBNiauraRBrownRA, editors. The tobacco dependence treatment handbook. New York (NY): Guilford Press; 2003.
18.
BienerLAbramsDB. The contemplation ladder: Validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10(5):360–365.
19.
HitsmanBAbramsDBShadelWG, Depressive symptoms and readiness to quit smoking among cigarette smokers in outpatient alcohol treatment. Psychol Addict Behav. 2002;16(3):264–268.
20.
HeathertonTFKozlowskiLTFreckerRC, The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–1127.
21.
BuckleyTCMozleySLHolohanDR, A psychometric evaluation of the Fagerstrom Test for Nicotine Dependence in PTSD smokers. Addict Behav. 2005;30(5):1029–1033.
22.
WeinbergerAHReutenauerELAllenTM, Reliability of the Fagerstrom Test for Nicotine Dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for Smoking Urges in smokers with and without schizophrenia. Drug Alcohol Depend. 2007;86(2–3):278–282.
23.
HughesJRHatsukamiD.Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289–294.
24.
TiffanySTDrobesDJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict. 1991;86(11):1467–1476.
25.
NiauraR.Nonpharmacologic therapy for smoking cessation: Characteristics and efficacy of current approaches. Am J Med. 2008;121(4 Suppl 1):S11–S19.
26.
ZiedonisDMGeorgeTP. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23(2):247–254.
27.
EvinsAEMaysVKRigottiNA, A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3(4):397–403.
28.
EvinsAECatherCDeckersbachT, A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25(3):218–225.
29.
HallSMMunozRFReusVI, Mood management and nicotine gum in smoking treatment: A therapeutic contact and placebo-controlled study. J Consult Clin Psychol. 1996;64(5):1003–1009.
30.
BrownRAKahlerCWNiauraR, Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol. 2001;69(3):471–480.
31.
Le FollBGeorgeTP. Treatment of tobacco dependence: Integrating recent progress into practice. CMAJ. 2007;177(11):1373–1380.
32.
SchnollRALermanC.Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs. 2006;11(3):429–444.
33.
CoxLSTiffanySTChristenAG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3(1):7–16.
34.
GeorgeTPO'MalleySS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci. 2004;25(1):42–48.
35.
GourlaySGBenowitzNL. Is clonidine an effective smoking cessation therapy?Drugs. 1995;50(2):197–207.
36.
HughesJRSteadLFLancasterT.Nortriptyline for smoking cessation: A review. Nicotine Tob Res. 2005;7(4):491–499.
37.
US Food and Drug Administration. Public Health Advisory—important information on Chantix (varenicline) [Internet]. [place unknown]: US FDA; 2008 [cited 2008 Oct 30]. Available from: http://www.fda.gov/cder/drug/advisory/varenicline.htm.
38.
GonzalesDRennardSINidesM, Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA. 2006;296(1):47–55.
39.
JorenbyDEHaysJTRigottiNA, Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA. 2006;296(1):56–63.
40.
NidesMOnckenCGonzalesD, Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561–1568.
41.
OnckenCGonzalesDNidesM, Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166(15):1571–1577.
42.
EvinsAEGoffDC. Varenicline treatment for smokers with schizophrenia: A case series. J Clin Psychiatry. 2008;69(6):1016.
43.
StapletonJAWatsonLSpirlingLI, Varenicline in the routine treatment of tobacco dependence: A pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103(1):146–154.
44.
MorisanoDBacherIAudrain-McGovernJ, Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Can J Psychiatry. 2009;54(6):356–367.
45.
ChouKRChenRLeeJF, The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud. 2004;41(3):321–330.
46.
EvinsAECatherCCulhaneMA, A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27(4):380–386.
47.
HorstDKleinMWWilliamsD, Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treat. 2005;1(4):349–355.
48.
EvinsAECatherCRigottiNA, Two-year follow-up of a smoking cessation trial in patients with schizophrenia: Increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004;65(3):307–311; quiz 452–303.
49.
GeorgeTPVessicchioJCTermineA, A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52(1):53–61.
50.
WarnerCShoaibM.How does bupropion work as a smoking cessation aid?Addict Biol. 2005;10(3):219–231.
51.
WeinerEBallMPSummerfeltA, Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry. 2001;158(4):635–637.
52.
GeorgeTPVessicchioJCSaccoKA, A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63(11):1092–1096.
53.
ActonGSProchaskaJJKaplanAS, Depression and stages of change for smoking in psychiatric outpatients. Addict Behav. 2001;26(5):621–631.
54.
HaugNAHallSMProchaskaJJ, Acceptance of nicotine dependence treatment among currently depressed smokers. Nicotine Tob Res. 2005;7(2):217–224.
55.
ProchaskaJJRossiJSReddingCA, Depressed smokers and stage of change: Implications for treatment interventions. Drug Alcohol Depend. 2004;76(2):143–151.
56.
HallSMTsohJYProchaskaJJ, Treatment for cigarette smoking among depressed mental health outpatients: A randomized clinical trial. Am J Public Health. 2006;96(10):1808–1814.
57.
ProchaskaJODiClementeCCNorcrossJC. In search of how people change. Applications to addictive behaviors. Am Psychologist. 1992;47(9):1102–1114.
58.
WeinbergerAHVessicchioJCSaccoKA, A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. J Clin Psychopharmacol. 2008;28(5):584–587.
59.
McFallMAtkinsDCYoshimotoD, Integrating tobacco cessation treatment into mental health care for patients with posttraumatic stress disorder. Am J Addict. 2006;15(5):336–344.
60.
McFallMSaxonAJThaneemit-ChenS, Integrating smoking cessation into mental health care for post-traumatic stress disorder. Clin Trials. 2007;4(2):178–189.
61.
McFallMSaxonAJThompsonCE, Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. Am J Psychiatry. 2005;162(7):1311–1319.
62.
ZvolenskyMJLejuezCWKahlerCW, Nonclinical panic attack history and smoking cessation: An initial examination. Addict Behav. 2004;29(4):825–830.
63.
VessicchioJCTermineAGeorgeTP. Smoking cessation and panic attacks: A report of 2 cases. J Clin Psychiatry. 2002;63(7):594–595.
64.
BakerARichmondRHaileM, A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163(11):1934–1942.
65.
GallagherSMPennPESchindlerE, A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses. J Psychoactive Drugs. 2007;39(4):487–497.
66.
CurrieSRKarltynJLussierD, Outcome from a community-based smoking cessation program for persons with serious mental illness. Community Ment Health J. 2008;44(3):187–194.
67.
GrantKMKelleySSSmithLM, Bupropion and nicotine patch as smoking cessation aids in alcoholics. Alcohol. 2007;41(5):381–391.
68.
BoboJKMcIlvainHELandoHA, Effect of smoking cessation counseling on recovery from alcoholism: Findings from a randomized community intervention trial. Addiction. 1998;93(6):877–887.
69.
KalmanDHayesKColbySM, Concurrent versus delayed smoking cessation treatment for persons in early alcohol recovery. A pilot study. J Subst Abuse Treat. 2001;20(3):233–238.
70.
GaritiPAltermanAMulvaneyF, Nicotine intervention during detoxification and treatment for other substance use. Am J Drug Alcohol Abuse. 2002;28(4):671–679.
71.
ShoptawSRotheram-FullerEYangX, Smoking cessation in methadone maintenance. Addiction. 2002;97(10):1317–1328; discussion 1325.
72.
JosephAMWillenbringMLNugentSM, A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol. 2004;65(6):681–691.
TideyJWReisRK. People with mental illness. In: HigginsSTSilvermanKHeilSH, editors. Contingency management in substance abuse treatment. New York (NY): Guilford Press; 2008. p 202–221.
75.
HughesJRCarpenterMJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res. 2006;8(6):739–749.
76.
Department of Health and Human Services. The health consequences of smoking: A report of the surgeon general. Washington (DC): Centers for Disease Control and Prevention [Atlanta, GA], National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
77.
ThorsteinssonHSGillinJCPattenCA, The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology. 2001;24(4):350–358.
78.
DolanSLSaccoKATermineA, Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr Res. 2004;70(2–3):263–275.
79.
FreedmanRCoonHMyles-WorsleyM, Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 1997;94(2):587–592.
80.
LevinEDWilsonWRoseJE, Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996;15(5):429–436.
81.
DesaiHDSeaboltJJannMW. Smoking in patients receiving psychotropic medications: A pharmacokinetic perspective. CNS Drugs. 2001;15(6):469–494.
82.
de LeonJ.Atypical antipsychotic dosing: The effect of smoking and caffeine. Psychiatr Serv. 2004;55(5):491–493.
83.
LiaoDLYangJYLeeSM, Smoking in chronic schizophrenic inpatients in Taiwan. Neuropsychobiology. 2002;45(4):172–175.
84.
LandowLSzetelaBKnowMA. Reducing smoking among psychiatric inpatients: A survey of psychiatrists. Am J Public Health. 1995;85(8 Pt 1):1169.
85.
PearlmanT.Impact of a smoking ban on a locked psychiatric unit. J Clin Psychiatry. 1997;58(4):179.
86.
LawnSPolsR.Smoking bans in psychiatric inpatient settings? A review of the research. Aust N Z J Psychiatry. 2005;39(10):866–885.
87.
WilliamsJMZiedonisDM. Snuffing out tobacco dependence. Ten reasons behavioral health providers need to be involved. Behav Healthc. 2006;26(5):27–31.
88.
WilliamsJM. Eliminating tobacco use in mental health facilities: Patients' rights, public health, and policy issues. JAMA. 2008;299(5):571–573.
89.
MillerWRollnickS.Motivational interviewing. New York (NY): Guildford Press; 1991.
90.
SteinbergMLZiedonisDMKrejciJA, Motivational interviewing with personalized feedback: A brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol. 2004;72(4):723–728.
91.
RollJMHigginsSTSteingardS, Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: A feasibility study. Exp Clin Psychopharmacol. 1998;6(2):157–161.
92.
TideyJWO'NeillSCHigginsST. Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Exp Clin Psychopharmacol. 2002;10(3):241–247.
93.
HallSMHumfleetGLReusVI, Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry. 2004;161(11):2100–2107.
94.
SteinbergMBSchmelzerACRichardsonDL, The case for treating tobacco dependence as a chronic disease. Ann Intern Med. 2008;148(7):554–556.
95.
MontoyaIDVocciF.Medications development for the treatment of nicotine dependence in individuals with schizophrenia. J Dual Diagn. 2007;3:113–150.
